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Abstract
Puumala virus infection causes epidemic nephropathia (NE), a
certain type of haemorrhagic fever with renal syndrome (HFRS).
Myopic shift is considered a pathognomonic sign of NE and
HFRS but rates of ocular involvement vary. The aim of the study
was to evaluate whether clinical and laboratory ﬁndings are
associated with ophthalmic involvement in NE in Austria. We
found that blurred vision and myopic shift are frequent in Puu-
mala virus infections in Austria but are independent of disease
severity.
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The vast majority of European Hantavirus cases are caused
by Puumala virus, carried by the bank vole and responsible
for Nephropathia epidemica (NE) [1]. The aim of the study
was to evaluate whether clinical and laboratory ﬁndings are
associated with ophthalmic involvement and disease severity
in NE in Austria.
Patients examined at the emergency room of the univer-
sity hospital of Graz were eligible for study inclusion. Graz is
located in the south-east of Austria where a vast majority of
Austrian Puumala virus infections have been identiﬁed to
date [2]. In the case of clinical suspicion of NE, diagnosis was
established within 12 h after presentation using antibody
testing (Point-of-care PUUMALA; Reagena, Toivala, Finland).
Patients with a positive antibody test were examined by oph-
thalmologists within the same day. Ocular examination com-
prised determination of refraction (compared with baseline
refraction) and best-corrected visual acuity, intraocular pres-
sure using Goldmann applanation tonometry and split lamp
examination. Patients were examined up to four times in
certain cases until ocular manifestations returned to normal
or to documented baseline refraction determined prior to
NE. Body temperature was measured three times a day and
additionally whenever the patient felt febrile. In addition,
hypotension (<90 mmHG), bradycardia (<60 bpm) and tachy-
cardia (>100 bpm) were measured three times a day. Fur-
thermore, abnormal ﬁndings in liver function tests (AST,
ALT), gamma-glutamyl transferase (GGT) and other labora-
tory parameters such as creatinine, urea, leukocytes, throm-
bocytes, CRP and LDH were assessed daily until discharge.
The highest values (the lowest value for thrombocytes) were
used for statistical calculations as described below.
Eighteen patients with NE (aged 18–68 years, median
40.5 years; two female, 16 male) were investigated. Patients
had their ﬁrst contact and investigation in the emergency
room between day 1 and 14 (median, day 4) after onset of
NE. Two patients had systemic symptoms (e.g. fever, cepha-
lea, nausea) for 14 days prior to presentation and both had
ophthalmic involvement. Myopic shift (=change in refraction
power towards myopic direction) occurred in 9/18 (50%)
patients; in eight in both eyes, in one patient in the left eye
only. The average myopic shift was )2.75 diopters (maxi-
mum )3.50, minimum )1.50) in the right eye and )2.54
diopters (maximum )4.00, minimum )1.00) in the left eye.
Blurred vision occurred in 14/18 (78%), conjunctival injection
in 4/18 (22%), and subconjunctival haemorrhages in 1/18
(6%) patients. Intraocular pressure was normal in all eyes. All
ocular manifestations were transient and did not require any
treatment.
Fever (>37.8C) was observed in 15/18 (83%) patients
(median duration 7.5 days; minimum 0, maximum 15). The
rates of bradycardia, tachycardia and hypotonia are depicted
in Table 1. Three out of eighteen (17%) patients required
haemodialysis; none of these three had myopic shift. Labora-
tory values are depicted in Table 2. There was no signiﬁcant
difference in clinical signs and symptoms and laboratory
parameters between patients with and without myopic shift
or with and without blurred vision (chi-square test for cate-
gorical variables; Mann–Whitney U-test for non-normally dis-
tributed continuous parameters). Only for C-reactive protein
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(CRP) was a difference found, with higher values measured
in patients without blurred vision (p 0.03).
Myopic shift was less frequent in our study (50%) com-
pared with a Finnish study (78%) [3]. On the other hand, the
average myopic shift in our study ()2.75 diopters right eye,
)2.54 diopters left eye) was more pronounced than in two
other Finnish studies [3,4]. The rate of conjunctival haemor-
rhages in our study (6%) was similar to previous rates (2%
and 4%, respectively) [3,5]. Conjunctival injection in our
study (22%) resembled previous ﬁndings (27%) [5], but was
lower compared with another Finnish study (87%) [3]. The
frequency of ocular ﬁndings in Puumala virus infections
seems to be diverse in different European countries, so local
epidemiological data are necessary to interpret these clinical
ﬁndings correctly. It is not clear whether differences in
occurrence rates and in severity of ocular symptoms in dif-
ferent countries are due to variant virus strains, predisposi-
tion of inhabitants or diagnostic differences. The latter,
however, is unlikely as the serological tests applied in our
study (i.e. Point-of-care PUUMALA; Reagena) have also been
used in previous European investigations [6,7]. In contrast to
recent studies [3], we also evaluated patients with renal fail-
ure requiring haemodialysis and none had myopic shift. Previ-
ously, shallowing of the anterior chamber, thickening of the
lens, changes in osmolarity of lens and aqueous humour,
length of vitreous cavity and increased tissue permeability
have been considered as possible mechanisms for ocular
symptoms in NE [3]. Interestingly, one patient in our study
presented myopic shift and decreased anterior chamber
depth only in one eye. This is in contrast to the assumption
that myopic shift is part of a systemic infection by Puumala
virus [4]. This ﬁnding may argue for a local ocular manifesta-
tion as the causative pathogenesis of myopic shift in NE or
reﬂects differences in time of resolution of myopic shift in
both eyes. In four patients with blurred vision myopic shift
was not detected. It is unclear whether this was due to the
fact that refraction had already normalized at the time of
examination or a slightly oedematous lens was still present,
or was due to non-ophthalmic reasons in Puumala virus
infections; one reason could be involvement of the CNS as
previously published [6,8–11].
In conclusion, ocular symptoms (especially blurred vision
and myopic shift) are frequent in Puumala virus infection in
Austria and may therefore be important in diagnosis of the
disease. Except for higher CRP values in patients without
blurred vision, there was no difference in clinical variables
and laboratory parameters in patients with or without
blurred vision/myopic shift, suggesting that both are indepen-
dent of disease severity in Puumala virus infections.
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TABLE 1. Clinical signs in patients with and without myopic shift/blurred vision
Patients with
myopic shift, %
Patients without
myopic shift, % p-value
Patients with
blurred vision, %
Patients without
blurred vision, % p-value
Hypotonia (<90 mmHG syst) 11 (1/9) 0 (0/9) 0.303 7 (1/14) 0 (0/4) 0.582
Tachycardia (>100 bpm) 11 (1/9) 33 (3/9) 0.257 21 (3/14) 25 (1/4) 0.88
Bradycardia (<50 bpm) 44 (4/9) 33 (3/9) 0.629 36 (5/14) 50 (2/4) 0.605
Fever (>37.8C) 89 (8/9) 78 (7/9) 0.527 86 (12/14) 75 (3/4) 0.612
TABLE 2. Laboratory values in patients with and without myopic shift/blurred vision
Variable (normal range)
Patients with
myopic shift (n = 9);
median (range)
Patients without
myopic shift (n = 9);
median (range) p-value
Patients with
blurred vision (n = 14);
median (range)
Patients without
blurred vision (n = 4);
median (range) p-value
AST (<30) U/L 61 (31–93) 66 (26–193) 0.269 65 (26–193) 88.5 (53–119) 0.222
ALT (<35) U/L 83 (20–134) 84 (17–305) 0.353 83 (17–305) 132.5 (67–233) 0.089
GGT (<38) U/L 93 (27–895) 66 (16–377) 1.000 93 (16–895) 90 (32–153) 0.710
Creatinine (0.5–1) mg/dL 3.5 (1.1–6.7) 1.9 (0.8–10.2) 0.566 3.5 (0.8–10.2) 3.75 (1.4–8.9) 0.632
Urea (10–45) mg/dL 137 (30–245) 66 (21–207) 0.310 125 (21–245) 90 (61–158) 1.000
Leucocytes (4.4–11.3)
G/L (highest value)
11.98 (5.3–22.4) 10.6 (5–13.6) 0.691 11.98 (4.98–22.41) 10.41 (8.35–13.62) 0.832
Thrombocytes (1140–440)
G/L (lowest value)
42 (25–138) 83 (35–280) 0.122 51 (25–251) 67.5 (35–280) 0.559
CRP (<5) mg/L 64 (1–134) 66 (1–257) 0.791 63 (1–134) 170 (66–257) 0.026*
LDH (120–240) U/L 281 (190–682) 334 (165–550) 0.791 340 (165–682) 295 (240–340) 0.490
*CRP values higher in patients without blurred vision.
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